{"id":617799,"date":"2025-12-23T11:56:15","date_gmt":"2025-12-23T11:56:15","guid":{"rendered":"https:\/\/www.europesays.com\/fr\/617799\/"},"modified":"2025-12-23T11:56:15","modified_gmt":"2025-12-23T11:56:15","slug":"usa-les-valeurs-a-suivre-a-wall-street-23-12-2025-a-1106","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/fr\/617799\/","title":{"rendered":"USA-Les valeurs \u00e0 suivre \u00e0 Wall Street &#8211; 23\/12\/2025 \u00e0 11:06"},"content":{"rendered":"<p>\n Principales valeurs \u00e0 suivre<br \/>\nmardi \u00e0 Wall Street, o\u00f9 les contrats \u00e0 terme sur les principaux<br \/>\nindices sugg\u00e8rent une ouverture en hausse de 0,04% pour le Dow<br \/>\nJones<br \/>\n <a href=\"https:\/\/www.boursorama.com\/cours\/%24INDU\/\" target=\"_blank\" rel=\"noopener\"><br \/>\n  .DJI<br \/>\n <\/a><br \/>\n , de 0,08% pour le Standard &amp; Poor&rsquo;s-500<br \/>\n <a href=\"https:\/\/www.boursorama.com\/cours\/%24INX\/\" target=\"_blank\" rel=\"noopener\"><br \/>\n  .SPX<br \/>\n <\/a><br \/>\n et<br \/>\nde 0,11% pour le Nasdaq.\n<\/p>\n<p>\n * ELI LILLY<br \/>\n <a href=\"https:\/\/www.boursorama.com\/cours\/LLY\/\" target=\"_blank\" rel=\"noopener\"><br \/>\n  LLY.N<br \/>\n <\/a><br \/>\n &#8211; Le laboratoire danois Novo Nordisk\n<\/p>\n<p>\n <a href=\"https:\/\/www.boursorama.com\/cours\/1uNVOB.L\/\" target=\"_blank\" rel=\"noopener\"><br \/>\n  NOVOb.CO<br \/>\n <\/a><br \/>\n , qui cherche \u00e0 regagner le terrain perdu face \u00e0 son<br \/>\nrival am\u00e9ricain Eli Lilly, entend commercialiser son traitement<br \/>\namaigrissant Wegovy sous forme de comprim\u00e9 d\u00e8s janvier dans les<br \/>\npharmacies aux Etats-Unis, apr\u00e8s avoir re\u00e7u lundi l&rsquo;accord de<br \/>\nl&rsquo;autorit\u00e9 am\u00e9ricaine des m\u00e9dicaments (FDA) pour cette forme<br \/>\nd&rsquo;administration.\n<\/p>\n<p>\n * SECTEUR DE L&rsquo;IA &#8211; John Carreyrou, journaliste<br \/>\nd&rsquo;investigation au New York Times et connu pour avoir r\u00e9v\u00e9l\u00e9 des<br \/>\nfraudes au sein de la start-up Theranos, a port\u00e9 plainte lundi<br \/>\navec cinq autres auteurs contre xAI, Anthropic, Google, OpenAI,<br \/>\nMeta Platforms<br \/>\n <a href=\"https:\/\/www.boursorama.com\/cours\/META\/\" target=\"_blank\" rel=\"noopener\"><br \/>\n  META.O<br \/>\n <\/a><br \/>\n et Perplexity pour avoir utilis\u00e9 sans<br \/>\nautorisation leurs livres prot\u00e9g\u00e9s par le droit d&rsquo;auteur afin<br \/>\nd&rsquo;entra\u00eener leurs syst\u00e8mes d&rsquo;intelligence artificielle (IA).\n<\/p>\n<p>\n (R\u00e9dig\u00e9 par Diana Mandia, \u00e9dit\u00e9 par Kate Entringer)<\/p>\n","protected":false},"excerpt":{"rendered":"Principales valeurs \u00e0 suivre mardi \u00e0 Wall Street, o\u00f9 les contrats \u00e0 terme sur les principaux indices sugg\u00e8rent&hellip;\n","protected":false},"author":2,"featured_media":609392,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1589],"tags":[400,11,398,408,405,73,1866,403,402,399,404,12,401,406,1864,1865,1863,308,407],"class_list":{"0":"post-617799","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-etats-unis","8":"tag-action-cac-40","9":"tag-actualites","10":"tag-bourse-de-paris","11":"tag-boursorama","12":"tag-cotations","13":"tag-etats-unis","14":"tag-etats-unis-damerique","15":"tag-indices-devises","16":"tag-investir","17":"tag-investissement","18":"tag-marche-boursier","19":"tag-news","20":"tag-sicav","21":"tag-trackers","22":"tag-united-states","23":"tag-united-states-of-america","24":"tag-us","25":"tag-usa","26":"tag-warrants"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@fr\/115768759723242096","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/617799","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/comments?post=617799"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/posts\/617799\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media\/609392"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/media?parent=617799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/categories?post=617799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/fr\/wp-json\/wp\/v2\/tags?post=617799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}